Class Members Eligible for Neurontin Third Party Payor Settlement:
All third-party payors (“TPPs”) in the United States and its territories who purchased, paid for, administered, and/or reimbursed all or any portion of the price for Neurontin or for gabapentin sold by Greenstone LLC at any time from their first sale in the United States through the Effective Date for purposes other than resale.
The TPPs in the Class include, but are not limited to, insurance companies, healthcare benefit providers, health maintenance organizations, union health and welfare plans, self-funded health and welfare plans, and any other health benefit provider and/or entity that contracts with a health insurance company or other entity to serve as a third-party claims administrator to administer their prescription drug benefits, entities that may provide prescription drug benefits for current or former public employees and/or retirees, and private entities that provide pharmacy benefits for a state Medicaid program or Medicare Part D to the extent such entities are at risk for the payment of the cost of Neurontin prescriptions for their insureds; provided that the following TPPs are excluded from the Class: Kaiser Foundation Health Plan, Inc. and its subsidiaries; Aetna, Inc.; Blue Cross and Blue Shield of Alabama; Municipal Workers Compensation Fund, Inc.; and Union of Operating Engineers, Local No. 68 Welfare Fund.
Neurontin Third Party Payor Class Action Antitrust Settlement Case History:
The lawsuit relates to Defendants’ prescription drug Neurontin. The lawsuit claims that Defendants’ marketing violated the law by promoting the use of Neurontin for various uses and to treat various conditions for which it was: (1) not approved by the U.S. Food and Drug Administration (‘FDA”) and (2) was not effective. The lawsuit is not about the safety of Neurontin. The lawsuit alleges that, although the FDA approved Neurontin for a relatively narrow indication – as adjunctive therapy for adult epilepsy, and later, for treatment of post-herpetic neuralgia – Defendants sought to market Neurontin for several off-label uses in a variety of ways, including through false or misleading statements to physicians at conferences and medical education events, directly to physicians through sales representatives, and in medical publications. Plaintiffs also claim that Class Members were injured by paying more for Neurontin than they would have paid otherwise.
Defendants deny these claims, and deny they did anything wrong. Defendants have agreed to the Settlement solely to avoid further expense, inconvenience, and the burden of this litigation.
Our Class Action Settlement Services:
CAC Recovery navigates the complex intricacies of the Neurontin Third Party Payor Antitrust Litigation Settlement claims filing process to help businesses maximize their settlement recoveries.
Our class action settlement services include:
- Identifying class action claims where businesses may be eligible to file
- Filing the class action claim with supporting documentation
- Interacting with the class action Claims Administrator
- Providing updates on class action claim settlements status
- Resolving Claims Administrator questions on claims
- Reviewing the recovery to assure the correct compensation claims amount has been received
Our Guarantee: We Get Paid When You Recover – No hidden charges or up-front fees. We provide our class action settlements services based on a contingency fee.
Getting Started is easy! If you represent a business we’ll first have you fill out our ‘Get Started‘ form and a CAC representative will contact you within 24 hours to review your eligibility and walk you through the claims process.